Detalles de la búsqueda
1.
Final efficacy and safety results and biomarker analysis of a phase 2 study of cabozantinib in Japanese patients with advanced renal cell carcinoma.
Int J Clin Oncol
; 28(3): 416-426, 2023 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-36595123
2.
Prognostic value of PD-L1 expression in recurrent renal cell carcinoma after nephrectomy: a secondary analysis of the ARCHERY study.
Int J Clin Oncol
; 28(2): 289-298, 2023 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-36534263
3.
Phase I/II study of multipeptide cancer vaccine IMA901 after single-dose cyclophosphamide in Japanese patients with advanced renal cell cancer with long-term follow up.
Int J Urol
; 30(2): 176-180, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36305687
4.
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
N Engl J Med
; 380(12): 1116-1127, 2019 03 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-30779529
5.
Pembrolizumab plus axitinib versus sunitinib in metastatic renal cell carcinoma: outcomes of Japanese patients enrolled in the randomized, phase III, open-label KEYNOTE-426 study.
Int J Clin Oncol
; 27(1): 154-164, 2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-34800178
6.
Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial.
Lancet Oncol
; 21(12): 1563-1573, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-33284113
7.
Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: the OCUU-CRPC study.
Int J Clin Oncol
; 25(3): 486-494, 2020 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-31564004
8.
Cabozantinib in advanced renal cell carcinoma: A phase II, open-label, single-arm study of Japanese patients.
Int J Urol
; 27(11): 952-959, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32789967
9.
Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: study protocol for a multicenter randomized phase II trial (the OCUU-CRPC study).
BMC Cancer
; 19(1): 339, 2019 Apr 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30971225
10.
Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: a retrospective study.
Int J Clin Oncol
; 24(7): 848-856, 2019 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-30741370
11.
Comparison of efficacy and toxicity of second-line combination chemotherapy regimens in patients with advanced urothelial carcinoma.
Int J Clin Oncol
; 23(5): 944-950, 2018 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-29785621
12.
Near infrared fluorescence imaging system for laparoscopic partial nephrectomy.
Can J Urol
; 25(6): 9606-9613, 2018 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30553287
13.
Outcomes of indwelling metallic stents for malignant extrinsic ureteral obstruction.
Int J Urol
; 25(3): 258-262, 2018 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-29194771
14.
Heat shock protein 70 inhibitors suppress androgen receptor expression in LNCaP95 prostate cancer cells.
Cancer Sci
; 108(9): 1820-1827, 2017 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-28691182
15.
Carbonic anhydrase 2 is a novel invasion-associated factor in urinary bladder cancers.
Cancer Sci
; 108(3): 331-337, 2017 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-28004470
16.
Anti-PD-L1 treatment enhances antitumor effect of everolimus in a mouse model of renal cell carcinoma.
Cancer Sci
; 107(12): 1736-1744, 2016 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-27712020
17.
Add-on anticholinergic therapy for residual nocturia in patients with lower urinary tract symptoms receiving α1-blocker treatment: a multi-centre, prospective, randomised study.
World J Urol
; 33(5): 659-67, 2015 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-25224929
18.
Differences in adverse event profiles between everolimus and temsirolimus and the risk factors for non-infectious pneumonitis in advanced renal cell carcinoma.
Int J Clin Oncol
; 20(4): 790-5, 2015 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-25342378
19.
Prolonging survival in metastatic renal cell carcinoma patients treated with targeted anticancer agents: a single-center experience of treatment strategy modifications.
Can J Urol
; 22(3): 7798-804, 2015 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-26068628
20.
Editorial Comment to Efficacy and safety of first-line nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma: A multicenter retrospective study.
Int J Urol
; 27(12): 1100-1101, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-33006212